Update context and test results cases script

HBV_Eligibility_Results.csv

@@ -1,284 +1,249 @@
-Case ID,Age,Sex,Pregnancy Status,HBsAg,HBeAg,HBV DNA (IU/mL),ALT (U/L),Fibrosis/Cirrhosis Stage,Necroinflammation,Extrahepatic Manifestations,Immunosuppressive Therapy,Coinfections,Family History of HCC/Cirrhosis,Smoking,Comorbidities,Eligibility,Rationale
-Case1,28,M,No,Positive (36 months),Positive,8500000,120,F1,Moderate,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, with moderate necroinflammation (Grade A) [SASLT 2021, Page 6]
-- Meets criteria for treatment due to HBV DNA > 20,000 IU/mL and ALT > 2xULN (Grade B) [SASLT 2021, Page 6]
+Case ID,Age,Sex,Pregnancy Status,HBsAg,HBeAg,HBV DNA (IU/mL),ALT (U/L),Fibrosis/Cirrhosis Stage,Necroinflammation,Extrahepatic Manifestations,Immunosuppressive Therapy,Coinfections,Family History of HCC/Cirrhosis,Smoking,Comorbidities,Eligibility,Rationale,Eligibility from ACTIVATE 2,Rational from ACTIVATE 2
+Case1,28,M,No,Positive (36 months),Positive,8500000,120,F1,Moderate,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 20,000 IU/mL and ALT > 2xULN, regardless of fibrosis (Grade B) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6-9]
+- Consider patient's age and health status in treatment planning [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case2,45,F,No,Positive (60 months),Negative,15000,65,F1–F2,Moderate,No,,,No,No,Metabolic syndrome,True,"Eligibility and Rationale:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case2,45,F,No,Positive (60 months),Negative,15000,65,F1–F2,Moderate,No,,,No,No,Metabolic syndrome,,,eligible,"Eligibility and Rationale:
 - Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
-- Necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade D) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- Metabolic syndrome may require additional management alongside HBV treatment [SASLT 2021, Page 6]
+- Consider metabolic syndrome management alongside HBV treatment [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case3,52,M,No,Positive (120 months),Negative,3500,32,F2–F3,Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, moderate fibrosis (F2-F3), and chronic HBV infection (Grade A) [SASLT 2021, Page 6].
-- ALT is within normal limits but fibrosis stage supports treatment initiation (Grade A) [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case3,52,M,No,Positive (120 months),Negative,3500,32,F2–F3,Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL and moderate fibrosis (F2-F3) (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].
+- No extrahepatic manifestations or family history of HCC/cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case4,60,M,No,Positive (240 months),Negative,700,28,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: Cirrhosis (F4) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case4,60,M,No,Positive (240 months),Negative,700,28,F4 (compensated),Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient [SASLT 2021, Pages 6-10]
+- Consider risk of HCC due to cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case5,22,F,No,Positive (18 months),Positive,25000000,27,F0,,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA > 20,000 IU/mL but ALT ≤ 2xULN and age < 30 years (Grade B) [SASLT 2021, Page 6].
-- No significant fibrosis or necroinflammation (F0-F1, A0) and no family history of HCC or cirrhosis [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case5,22,F,No,Positive (18 months),Positive,25000000,27,F0,,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 20,000 IU/mL but ALT ≤ ULN and no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].
-
-Special Considerations:
-- None applicable to this patient.
+- Monitor every 3-6 months due to HBeAg-positive status and age < 30 years (Grade B) [SASLT 2021, Page 7]
 
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case6,40,M,No,Positive (84 months),Negative,900,22,F0–F1,,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+Case6,40,M,No,Positive (84 months),Negative,900,22,F0–F1,,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
 
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case7,31,F,Yes (28 weeks),Positive (48 months),Positive,500000,35,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis starting at 24-28 weeks (Grade D) [SASLT 2021, Page 10].
-- Eligible: HBeAg-positive chronic HBV infection with high HBV DNA levels (> 20,000 IU/mL) and age > 30 years (Grade D) [SASLT 2021, Page 6].
+Case7,31,F,Yes (28 weeks),Positive (48 months),Positive,500000,35,F1,Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Pregnant with HBV DNA > 100,000 IU/mL, requires antiviral prophylaxis (Grade D) [SASLT 2021, Page 10]
 
 Treatment Recommendations:
-- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10].
-- Preferred regimens for CHB treatment include TDF, TAF, or ETV monotherapy (Grade A) [SASLT 2021, Page 8].
+- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10]
 
 Monitoring and Follow-up:
-- Monitor HBV DNA and ALT levels every 3 months during pregnancy and postpartum (Grade D) [SASLT 2021, Page 7].
-- Assess treatment response and adjust therapy as needed per SASLT protocol [SASLT 2021, Page 7].
+- Monitor HBV DNA and ALT levels regularly during pregnancy [SASLT 2021, Page 10]
 
 Special Considerations:
-- Breastfeeding is permitted for HBsAg-positive women on TDF (Grade B) [SASLT 2021, Page 10].
+- Breastfeeding is permitted for HBsAg+ women on TDF (Grade B) [SASLT 2021, Page 10]
 
 References:
-- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy-related recommendations"
-Case8,35,M,No,Positive (72 months),Positive,9000000,33,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBeAg-positive chronic HBV infection, age > 30 years, persistently high HBV DNA levels (Grade D) [SASLT 2021, Page 6].
-- HBV DNA > 2,000 IU/mL and ALT ≤ ULN, meeting treatment criteria for HBeAg-positive patients > 30 years (Grade D) [SASLT 2021, Page 6].
+- Pages 9, 10: Pregnancy-related recommendations, treatment criteria"
+Case8,35,M,No,Positive (72 months),Positive,9000000,33,F1,Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBeAg-positive, >30 years, high HBV DNA, normal ALT (Grade D) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient.
+- Consider patient's age and high HBV DNA level in treatment decision [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case9,55,F,No,Positive (180 months),Negative,6200,45,F1–F2,Moderate,No,,,Yes (father HCC),No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
-- Family history of HCC or cirrhosis supports treatment initiation (Grade D) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case9,55,F,No,Positive (180 months),Negative,6200,45,F1–F2,Moderate,No,,,Yes (father HCC),No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis, and family history of HCC (Grade D) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient [SASLT 2021, Pages 6-10]
+- Family history of HCC increases risk, supporting treatment initiation [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case10,63,M,No,Positive (300 months),Negative,50,32,F4 (decompensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case10,63,M,No,Positive (300 months),Negative,50,32,F4 (decompensated),Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].
+- Consider risk of HCC due to cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case11,68,M,No,Positive (25 years),Negative,5800,41,F2,Mild,No,,,No,No,Diabetes,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (F2-F3) (Grade A) [SASLT 2021, Page 6]
-- Chronic HBV infection with significant liver disease warrants treatment initiation (Grade A) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case11,68,M,No,Positive (25 years),Negative,5800,41,F2,Mild,No,,,No,No,Diabetes,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL and moderate fibrosis (F2-F3) (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- Patient's age (68 years) and comorbidity (diabetes) may require closer monitoring for treatment-related side effects [SASLT 2021, Page 6]
+- Consider diabetes management in conjunction with HBV treatment [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case12,50,F,No,Positive,Negative,450,32,,Mild,No,Yes (tacrolimus),,No,No,Post-transplant,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case12,50,F,No,Positive,Negative,450,32,,Mild,No,Yes (tacrolimus),,No,No,Post-transplant,,,eligible,"Eligibility and Rationale:
+- Eligible: HBsAg-positive patient requires prophylaxis due to immunosuppression (Grade A) [SASLT 2021, Page 9]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Start antiviral prophylaxis with ETV, TDF, or TAF [SASLT 2021, Page 8, 9]
 
 Monitoring and Follow-up:
-- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+- Continue prophylaxis for ≥6 months after immunosuppression [SASLT 2021, Page 9]
 
 Special Considerations:
-- Immunosuppression: Consider prophylaxis if undergoing immunosuppressive therapy (Grade A) [SASLT 2021, Page 9].
+- Monitor for HBV reactivation risk due to post-transplant status [SASLT 2021, Page 9]
 
 References:
-- Pages 6, 7, 9: Treatment criteria, monitoring protocols, immunosuppression considerations"
-Case13,27,M,No,Positive (36 months),Negative,1700,55,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT > ULN but mild fibrosis and necroinflammation (Grade A) [SASLT 2021, Page 6]
+- Pages 8, 9: Prophylaxis criteria, drug options, monitoring"
+Case13,27,M,No,Positive (36 months),Negative,1700,55,F1,Mild,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT > ULN, but no significant fibrosis or family history [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
-
-Special Considerations:
-- None applicable to this patient [SASLT 2021, Pages 6-10]
+- Monitor every 3 months for the first year, then every 6 months (HBeAg-negative, HBV DNA ≥ 2,000 IU/mL) (Grade D) [SASLT 2021, Page 7]
 
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case14,44,F,No,Positive,Negative,3000,70,F2,Moderate,No,,HCV RNA positive,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6].
-- HBV-HCV coinfection requires concurrent or prior HBV treatment to prevent reactivation during DAA therapy (Grade A) [SASLT 2021, Page 9].
+Case14,44,F,No,Positive,Negative,3000,70,F2,Moderate,No,,HCV RNA positive,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Eligible: HBV-HCV coinfection with criteria for HBV treatment (Grade A) [SASLT 2021, Page 9]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor HBV DNA and ALT every 4-8 weeks during DAA therapy and three months post-therapy (Grade D) [SASLT 2021, Page 9].
-- Monitor treatment response per SASLT protocol (Grade A) [SASLT 2021, Page 7].
+- Monitor HBV DNA and ALT every 4-8 weeks during HCV treatment [SASLT 2021, Page 9]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- HBV-HCV coinfection requires close monitoring to prevent HBV reactivation during HCV treatment (Grade A) [SASLT 2021, Page 9].
+- Consider risk of HBV reactivation during HCV treatment with DAAs [SASLT 2021, Page 9]
 
 References:
 - Pages 6, 7, 8, 9: Treatment criteria, drugs, monitoring, HBV-HCV coinfection"
-Case15,33,M,No,Positive,Negative,25000,30,F1,Mild,No,,HIV positive,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].
+Case15,33,M,No,Positive,Negative,25000,30,F1,Mild,No,,HIV positive,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has HBV-HIV coinfection and should start ART (Grade A) [SASLT 2021, Page 9]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- ART regimen must include TDF- or TAF-based therapy (Grade A) [SASLT 2021, Page 9]
 
 Monitoring and Follow-up:
-- Monitor every 3 months for the first year, then every 6 months (HBeAg-negative, HBV DNA ≥ 2,000 IU/mL) (Grade D) [SASLT 2021, Page 7].
-
-Special Considerations:
-- HBV-HIV coinfection: ensure ART includes TDF- or TAF-based regimen (Grade A) [SASLT 2021, Page 9].
+- Monitor patient closely after ART initiation for immune reconstitution [SASLT 2021, Page 9]
 
 References:
-- Pages 6, 7, 9: Treatment criteria, monitoring protocols, HIV coinfection"
-Case16,30,F,Yes (30 weeks),Positive,Positive,40000,28,F0,,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
-- Pregnancy alone does not meet treatment criteria unless HBV DNA > 100,000 IU/mL at 24-28 weeks [SASLT 2021, Page 10].
+- Page 9: HBV-HIV coinfection management, ART regimens"
+Case16,30,F,Yes (30 weeks),Positive,Positive,40000,28,F0,,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 100,000 IU/mL, ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].
-- Assess HBV DNA and ALT levels regularly to evaluate disease progression [SASLT 2021, Page 6].
+- Monitor every 3-6 months due to HBeAg-positive status and age < 30 (Grade B) [SASLT 2021, Page 7]
 
 Special Considerations:
-- Consider antiviral prophylaxis with TDF if HBV DNA exceeds 100,000 IU/mL at 24-28 weeks of pregnancy [SASLT 2021, Page 10].
+- Pregnancy does not alter eligibility as HBV DNA is < 100,000 IU/mL [SASLT 2021, Page 10]
 
 References:
 - Pages 6, 7, 10: Treatment criteria, monitoring protocols, pregnancy considerations"
-Case17,39,M,No,Positive,Negative,4800,250,F1,Marked,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, regardless of HBeAg status (Grade A) [SASLT 2021, Page 6]
-- ALT > 2x ULN supports treatment initiation (Grade B) [SASLT 2021, Page 6]
+Case17,39,M,No,Positive,Negative,4800,250,F1,Marked,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, indicating chronic hepatitis B (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient [SASLT 2021, Pages 6-10]
+- No extrahepatic manifestations or family history of HCC/cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case18,49,F,No,Positive,Negative,2300,37,F1,Mild,No,,,Yes (mother cirrhosis),No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and family history of HCC or cirrhosis (Grade D) [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case18,49,F,No,Positive,Negative,2300,37,F1,Mild,No,,,Yes (mother cirrhosis),No,,,,,Error: 500 Server Error: Internal Server Error for url: https://moazx-hbv-ai-assistant.hf.space/assess
+Case19,56,M,No,Positive,Negative,10,30,F4 (compensated),Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
-
-Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
-
-Special Considerations:
-- Family history of HCC or cirrhosis increases the need for treatment to reduce long-term risks [SASLT 2021, Page 6].
-
-References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case19,56,M,No,Positive,Negative,10,30,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
-
-Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient.
+- Consider risk of HCC due to cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case20,41,F,No,Positive (10 years),Negative,1900,28,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case20,41,F,No,Positive (10 years),Negative,1900,28,F1,Mild,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Treatment not indicated at this time [SASLT 2021, Page 6]
@@ -286,151 +251,140 @@ Treatment Recommendations:
 Monitoring and Follow-up:
 - Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
 
-Special Considerations:
-- None applicable to this patient [SASLT 2021, Page 6]
-
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case21,56,F,No,Positive,Negative,0,20,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBsAg, regardless of HBV DNA and ALT levels (Grade A) [SASLT 2021, Page 6].
+Case21,56,F,No,Positive,Negative,0,20,F4 (compensated),Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with any detectable HBV DNA level (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as the preferred treatment options (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA, ALT, and fibrosis assessment [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable as the patient has no coinfections, immunosuppression, or other special conditions [SASLT 2021, Pages 6-10].
+- Consider risk of HCC due to cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case22,70,M,No,Positive (30 years),Negative,1800,27,F2,Mild,No,,,No,Yes (smoker),Hypertension,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, moderate fibrosis but does not meet treatment thresholds [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case22,70,M,No,Positive (30 years),Negative,1800,27,F2,Mild,No,,,No,Yes (smoker),Hypertension,,,eligible,"Eligibility and Rationale:
+- Eligible: Moderate fibrosis (F2-F3) with HBV DNA > 2,000 IU/mL (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
+
+Special Considerations:
+- Consider patient's age and comorbidities in treatment planning [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7: Treatment criteria, monitoring protocols"
-Case23,33,F,Yes (12 weeks),Positive,Positive,300000,40,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis (Grade D) [SASLT 2021, Page 10]
-- ALT > ULN and HBeAg-positive status further support treatment initiation (Grade A) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case23,33,F,Yes (12 weeks),Positive,Positive,300000,40,F1,Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Pregnant with HBV DNA > 100,000 IU/mL, requires antiviral prophylaxis (Grade D) [SASLT 2021, Page 10]
 
 Treatment Recommendations:
 - Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10]
-- Preferred regimens include TDF or TAF as monotherapy (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor HBV DNA and ALT levels every 3 months during treatment (Grade D) [SASLT 2021, Page 7]
-- Postpartum follow-up to assess treatment continuation or cessation [SASLT 2021, Page 10]
+- Monitor HBV DNA and ALT levels regularly during pregnancy [SASLT 2021, Page 10]
 
 Special Considerations:
-- Breastfeeding is permitted while on TDF therapy (Grade B) [SASLT 2021, Page 10]
+- Breastfeeding is permitted for HBsAg+ women on TDF (Grade B) [SASLT 2021, Page 10]
 
 References:
-- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy considerations"
-Case24,46,M,No,Positive (8 years),Negative,50000,48,F2,Moderate,Yes (vasculitis),,,No,No,,True,"Eligibility and Rationale:
+- Pages 9, 10: Pregnancy-related recommendations, treatment criteria"
+Case24,46,M,No,Positive (8 years),Negative,50000,48,F2,Moderate,Yes (vasculitis),,,No,No,,,,eligible,"Eligibility and Rationale:
 - Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
-- Extrahepatic manifestations further support treatment initiation (Grade D) [SASLT 2021, Page 6]
+- Eligible due to extrahepatic manifestations (Grade D) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response every 3-6 months per SASLT protocol (Grade B) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient.
+- Consider extrahepatic manifestations in treatment planning [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case25,58,F,No,Positive,Negative,2000,60,F2,Moderate,No,,,No,No,CKD stage 3,True,"Eligibility and Rationale:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case25,58,F,No,Positive,Negative,2000,60,F2,Moderate,No,,,No,No,CKD stage 3,,,eligible,"Eligibility and Rationale:
 - Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
-- Moderate necroinflammation (A2) and fibrosis (F2-F3) support treatment initiation (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response every 3-6 months per SASLT protocol [SASLT 2021, Page 7]
-- Assess HBV DNA, ALT, and fibrosis progression during follow-up [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- CKD stage 3: Prefer TAF over TDF due to better renal safety profile (Grade A) [SASLT 2021, Page 8]
+- Consider CKD stage 3 when selecting antiviral therapy [SASLT 2021, Page 8]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case26,29,M,No,Positive,Positive,2500000,33,F0,,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case26,29,M,No,Positive,Positive,2500000,33,F0,,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 3-6 months (HBeAg-positive, HBV DNA > 2,000 IU/mL, ALT ≤ ULN) (Grade B) [SASLT 2021, Page 7].
-
-Special Considerations:
-- None applicable to this patient.
+- Monitor every 3-6 months due to HBeAg-positive status and age < 30 (Grade B) [SASLT 2021, Page 7]
 
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case27,54,M,No,Positive,Negative,750,18,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
+Case27,54,M,No,Positive,Negative,750,18,F4 (compensated),Mild,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as the preferred treatment options (Grade A) [SASLT 2021, Page 8].
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable as the patient has no coinfections, immunosuppression, or other special conditions [SASLT 2021, Pages 6-10].
+- Consider risk of HCC due to cirrhosis [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case28,38,F,No,Positive,Negative,6000,80,F2,Moderate,No,,,No,No,Obesity,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6]
-- Necroinflammatory activity (A2) and fibrosis stage (F2-F3) further support treatment initiation (Grade A) [SASLT 2021, Page 6]
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case28,38,F,No,Positive,Negative,6000,80,F2,Moderate,No,,,No,No,Obesity,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months initially (Grade A) [SASLT 2021, Page 7]
-- Assess fibrosis progression and treatment adherence regularly (Grade A) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- Obesity may impact liver disease progression; consider lifestyle interventions alongside antiviral therapy [SASLT 2021, Page 6]
+- Consider obesity management as part of overall health strategy [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
-Case29,42,M,No,Positive,Negative,1200,25,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
-- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"
+Case29,42,M,No,Positive,Negative,1200,25,F1,Mild,No,,,No,No,,,,not eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]
 
 Treatment Recommendations:
-- Treatment not indicated at this time [SASLT 2021, Page 6].
+- Treatment not indicated at this time [SASLT 2021, Page 6]
 
 Monitoring and Follow-up:
-- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
 
 References:
 - Pages 6, 7: Treatment criteria, monitoring protocols"
-Case30,25,F,No,Positive (2 years),Positive,12000000,95,F1,Moderate,No,,,No,No,,True,"Eligibility and Rationale:
-- Eligible: HBV DNA > 20,000 IU/mL and ALT > 2xULN, regardless of fibrosis stage (Grade B) [SASLT 2021, Page 6]
-- Moderate necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]
+Case30,25,F,No,Positive (2 years),Positive,12000000,95,F1,Moderate,No,,,No,No,,,,eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 20,000 IU/mL and ALT > 2xULN, regardless of fibrosis (Grade B) [SASLT 2021, Page 6]
 
 Treatment Recommendations:
 - Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
 
 Monitoring and Follow-up:
-- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+- Monitor treatment response per SASLT protocol [SASLT 2021, Page 7]
 
 Special Considerations:
-- None applicable to this patient [SASLT 2021, Pages 6-10]
+- Consider patient's age and health status in treatment planning [SASLT 2021, Page 6]
 
 References:
-- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring"

HBV_Eligibility_TestCases- Model Answer VS Test(Sheet1).csv

@@ -0,0 +1,423 @@
+Case ID,Age,Sex,Pregnancy Status,HBsAg,HBV DNA (IU/mL),HBeAg,ALT (U/L),Fibrosis/Cirrhosis Stage,Necroinflammation,Extrahepatic Manifestations,Immunosuppressive Therapy,Coinfections,Family History of HCC/Cirrhosis,Smoking,Comorbidities,Eligibility,Rationale,Column1,Eligibility from ACTIVATE 2,Rational from ACTIVATE 2,Eligibility from ACTIVATE2,Rationale from ACTIVATE
+Case1,28,M,No,Positive (36 months),8500000,Positive,120,F1,Moderate,No,None,None,No,No,None,Eligible,"HBV DNA >20,000 and ALT >2�ULN � treat without biopsy.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, with moderate necroinflammation (Grade A) [SASLT 2021, Page 6]
+- Meets criteria for treatment due to HBV DNA > 20,000 IU/mL and ALT > 2xULN (Grade B) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6-9]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case2,45,F,No,Positive (60 months),15000,Negative,65,F1�F2,Moderate,No,None,None,No,No,Metabolic syndrome,Eligible,"Chronic hepatitis B (HBV DNA >2,000 and ALT >ULN).",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade D) [SASLT 2021, Page 7]
+
+Special Considerations:
+- Metabolic syndrome may require additional management alongside HBV treatment [SASLT 2021, Page 6]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case3,52,M,No,Positive (120 months),3500,Negative,32,F2�F3,Mild,No,None,None,No,No,None,Eligible,"HBV DNA >2,000 with moderate fibrosis � treat even if ALT normal.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, moderate fibrosis (F2-F3), and chronic HBV infection (Grade A) [SASLT 2021, Page 6].
+- ALT is within normal limits but fibrosis stage supports treatment initiation (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case4,60,M,No,Positive (240 months),700,Negative,28,F4 (compensated),Mild,No,None,None,No,No,None,Eligible,Any detectable HBV DNA in cirrhosis � treat regardless of ALT.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: Cirrhosis (F4) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Pages 6-10]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case5,22,F,No,Positive (18 months),25000000,Positive,27,F0,None,No,None,None,No,No,None,Not Eligible,Immune-tolerant <30 years � monitor.,"While the guidelines state patients >30 years with HBeAg-positive chronic HBV infection may be treated regardless of histology, this patient has HBV DNA >20,000 IU/mL. Although ALT is not >2�ULN, the extremely high viral load (25 million IU/mL) and moderate necroinflammation warrant treatment consideration. The ""immune tolerant"" label may be premature without confirming truly minimal inflammation.",,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 20,000 IU/mL but ALT ≤ 2xULN and age < 30 years (Grade B) [SASLT 2021, Page 6].
+- No significant fibrosis or necroinflammation (F0-F1, A0) and no family history of HCC or cirrhosis [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable to this patient.
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case6,40,M,No,Positive (84 months),900,Negative,22,F0�F1,None,No,None,None,No,No,None,Not Eligible,"HBeAg-negative infection with HBV DNA <2,000 and normal ALT � observe.",,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case7,31,F,Yes (28 weeks),Positive (48 months),500000,Positive,35,F1,Mild,No,None,None,No,No,None,Eligible,"Pregnancy with HBV DNA >100,000 IU/mL � start prophylaxis.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis starting at 24-28 weeks (Grade D) [SASLT 2021, Page 10].
+- Eligible: HBeAg-positive chronic HBV infection with high HBV DNA levels (> 20,000 IU/mL) and age > 30 years (Grade D) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10].
+- Preferred regimens for CHB treatment include TDF, TAF, or ETV monotherapy (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor HBV DNA and ALT levels every 3 months during pregnancy and postpartum (Grade D) [SASLT 2021, Page 7].
+- Assess treatment response and adjust therapy as needed per SASLT protocol [SASLT 2021, Page 7].
+
+Special Considerations:
+- Breastfeeding is permitted for HBsAg-positive women on TDF (Grade B) [SASLT 2021, Page 10].
+
+References:
+- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy-related recommendations"
+Case8,35,M,No,Positive (72 months),9000000,Positive,33,F1,Mild,No,None,None,No,No,None,Eligible,HBeAg-positive infection >30 years � treat even with normal ALT.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBeAg-positive chronic HBV infection, age > 30 years, persistently high HBV DNA levels (Grade D) [SASLT 2021, Page 6].
+- HBV DNA > 2,000 IU/mL and ALT ≤ ULN, meeting treatment criteria for HBeAg-positive patients > 30 years (Grade D) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable to this patient.
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case9,55,F,No,Positive (180 months),6200,Negative,45,F1�F2,Moderate,No,None,None,Yes (father HCC),No,None,Eligible,"HBV DNA >2,000 with ALT >ULN; family history supports treatment.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Family history of HCC or cirrhosis supports treatment initiation (Grade D) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Pages 6-10]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case10,63,M,No,Positive (300 months),50,Negative,32,F4 (decompensated),Mild,No,None,None,No,No,None,Eligible,Decompensated cirrhosis with any detectable HBV DNA � treat.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case11,68,M,No,Positive (25 years),5800,Negative,41,F2,Mild,No,None,None,No,No,Diabetes,Eligible,"DNA >2,000 with ALT >ULN and F?2 � treat.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (F2-F3) (Grade A) [SASLT 2021, Page 6]
+- Chronic HBV infection with significant liver disease warrants treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7]
+
+Special Considerations:
+- Patient's age (68 years) and comorbidity (diabetes) may require closer monitoring for treatment-related side effects [SASLT 2021, Page 6]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case12,50,F,No,Positive,450,Negative,32,N/A,Mild,No,Yes (tacrolimus),None,No,No,Post-transplant,Eligible,Immunosuppressed post-transplant � prophylaxis required.,,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+
+Special Considerations:
+- Immunosuppression: Consider prophylaxis if undergoing immunosuppressive therapy (Grade A) [SASLT 2021, Page 9].
+
+References:
+- Pages 6, 7, 9: Treatment criteria, monitoring protocols, immunosuppression considerations"
+Case13,27,M,No,Positive (36 months),1700,Negative,55,F1,Mild,No,None,None,No,No,None,Not Eligible,"HBV DNA <2,000; borderline ALT � monitor.","While HBV DNA is <2,000 IU/mL, the ALT is clearly elevated (55 U/L, >ULN). This represents active hepatitis with evidence of liver inflammation and fibrosis. The guidelines recommend treatment for chronic hepatitis B with ALT >ULN and at least moderate necroinflammation or fibrosis. This case warrants closer evaluation and likely treatment.",,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT > ULN but mild fibrosis and necroinflammation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6]
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Pages 6-10]
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case14,44,F,No,Positive,3000,Negative,70,F2,Moderate,No,None,HCV RNA positive,No,No,None,Eligible,Treat HBV in all HBV/HCV coinfected patients.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6].
+- HBV-HCV coinfection requires concurrent or prior HBV treatment to prevent reactivation during DAA therapy (Grade A) [SASLT 2021, Page 9].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor HBV DNA and ALT every 4-8 weeks during DAA therapy and three months post-therapy (Grade D) [SASLT 2021, Page 9].
+- Monitor treatment response per SASLT protocol (Grade A) [SASLT 2021, Page 7].
+
+Special Considerations:
+- HBV-HCV coinfection requires close monitoring to prevent HBV reactivation during HCV treatment (Grade A) [SASLT 2021, Page 9].
+
+References:
+- Pages 6, 7, 8, 9: Treatment criteria, drugs, monitoring, HBV-HCV coinfection"
+Case15,33,M,No,Positive,25000,Negative,30,F1,Mild,No,None,HIV positive,No,No,None,Eligible,Treat all HIV/HBV coinfected patients.,,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 3 months for the first year, then every 6 months (HBeAg-negative, HBV DNA ≥ 2,000 IU/mL) (Grade D) [SASLT 2021, Page 7].
+
+Special Considerations:
+- HBV-HIV coinfection: ensure ART includes TDF- or TAF-based regimen (Grade A) [SASLT 2021, Page 9].
+
+References:
+- Pages 6, 7, 9: Treatment criteria, monitoring protocols, HIV coinfection"
+Case16,30,F,Yes (30 weeks),Positive,40000,Positive,28,F0,None,No,None,None,No,No,None,Not Eligible,"Pregnant but DNA <100,000 IU/mL � monitor only.",,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+- Pregnancy alone does not meet treatment criteria unless HBV DNA > 100,000 IU/mL at 24-28 weeks [SASLT 2021, Page 10].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].
+- Assess HBV DNA and ALT levels regularly to evaluate disease progression [SASLT 2021, Page 6].
+
+Special Considerations:
+- Consider antiviral prophylaxis with TDF if HBV DNA exceeds 100,000 IU/mL at 24-28 weeks of pregnancy [SASLT 2021, Page 10].
+
+References:
+- Pages 6, 7, 10: Treatment criteria, monitoring protocols, pregnancy considerations"
+Case17,39,M,No,Positive,4800,Negative,250,F1,Marked,No,None,None,No,No,None,Eligible,"ALT >2�ULN and DNA >2,000 IU/mL � immune-active.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, regardless of HBeAg status (Grade A) [SASLT 2021, Page 6]
+- ALT > 2x ULN supports treatment initiation (Grade B) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Pages 6-10]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case18,49,F,No,Positive,2300,Negative,37,F1,Mild,No,None,None,Yes (mother cirrhosis),No,None,Eligible,Borderline case with family history � treat per guideline consideration.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and family history of HCC or cirrhosis (Grade D) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
+
+Special Considerations:
+- Family history of HCC or cirrhosis increases the need for treatment to reduce long-term risks [SASLT 2021, Page 6].
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case19,56,M,No,Positive,10,Negative,30,F4 (compensated),Mild,No,None,None,No,No,None,Eligible,Cirrhosis requires lifelong antiviral therapy.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable to this patient.
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case20,41,F,No,Positive (10 Months),1900,Negative,28,F1,Mild,No,None,None,No,No,None,Not Eligible,Seroconverted with low DNA � continue monitoring only.,,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6]
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Page 6]
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case21,70,M,No,Positive (30 Month),1800,Negative,27,F2,Mild,No,None,None,No,Yes (smoker),Hypertension,Not Eligible,"Older age and fibrosis ?F2 does not warrant treatment even with low DNA. Monitor (ALT 6�12 mo, HBV DNA and fibrosis yearly).",,,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, moderate fibrosis but does not meet treatment thresholds [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case22,33,F,Yes (12 weeks),Positive,300000,Positive,40,F1,Mild,No,None,None,No,No,None,Not Eligible,Pregnancy early trimester � initiate prophylaxis only in 3rd trimester.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis (Grade D) [SASLT 2021, Page 10]
+- ALT > ULN and HBeAg-positive status further support treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10]
+- Preferred regimens include TDF or TAF as monotherapy (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor HBV DNA and ALT levels every 3 months during treatment (Grade D) [SASLT 2021, Page 7]
+- Postpartum follow-up to assess treatment continuation or cessation [SASLT 2021, Page 10]
+
+Special Considerations:
+- Breastfeeding is permitted while on TDF therapy (Grade B) [SASLT 2021, Page 10]
+
+References:
+- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy considerations"
+Case23,46,M,No,Positive (8 Months),50000,Negative,48,F2,Moderate,Yes (vasculitis),None,None,No,No,None,Eligible,Presence of extrahepatic manifestation � treat.,,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Extrahepatic manifestations further support treatment initiation (Grade D) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response every 3-6 months per SASLT protocol (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient.
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case24,58,F,No,Positive,2000,Negative,60,F2,Moderate,No,None,None,No,No,CKD stage 3,Eligible,"HBV DNA Borderline with comorbidities, ALT >ULN and F?2 � treat.",,,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Moderate necroinflammation (A2) and fibrosis (F2-F3) support treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response every 3-6 months per SASLT protocol [SASLT 2021, Page 7]
+- Assess HBV DNA, ALT, and fibrosis progression during follow-up [SASLT 2021, Page 7]
+
+Special Considerations:
+- CKD stage 3: Prefer TAF over TDF due to better renal safety profile (Grade A) [SASLT 2021, Page 8]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case25,29,M,No,Positive,2500000,Positive,33,F0,None,No,None,None,No,No,None,Not Eligible,"Immune-tolerant phase, <30 years � monitor.",,Not Eligible,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 3-6 months (HBeAg-positive, HBV DNA > 2,000 IU/mL, ALT ≤ ULN) (Grade B) [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable to this patient.
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case26,54,M,No,Positive,750,Negative,18,F4 (compensated),Mild,No,None,None,No,No,None,Eligible,Any detectable DNA in cirrhosis � treat.,,Eligible,,Eligible,"Eligibility and Rationale:
+- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as the preferred treatment options (Grade A) [SASLT 2021, Page 8].
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].
+
+Special Considerations:
+- None applicable as the patient has no coinfections, immunosuppression, or other special conditions [SASLT 2021, Pages 6-10].
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case27,38,F,No,Positive,6000,Negative,80,F2,Moderate,No,None,None,No,No,Obesity,Eligible,"ALT >2�ULN and DNA >2,000 IU/mL � treat.",,Eligible,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6]
+- Necroinflammatory activity (A2) and fibrosis stage (F2-F3) further support treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months initially (Grade A) [SASLT 2021, Page 7]
+- Assess fibrosis progression and treatment adherence regularly (Grade A) [SASLT 2021, Page 7]
+
+Special Considerations:
+- Obesity may impact liver disease progression; consider lifestyle interventions alongside antiviral therapy [SASLT 2021, Page 6]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+Case28,42,M,No,Positive (6 Months),1200,Negative,25,F1,Mild,No,None,None,No,No,None,Not Eligible,Inactive infection with low DNA and normal ALT � monitor.,,Not Eligible,,Not Eligible,"Eligibility and Rationale:
+- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].
+
+Treatment Recommendations:
+- Treatment not indicated at this time [SASLT 2021, Page 6].
+
+Monitoring and Follow-up:
+- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].
+
+References:
+- Pages 6, 7: Treatment criteria, monitoring protocols"
+Case29,25,F,No,Positive (2 years),12000000,Positive,95,F1,Moderate,No,None,None,No,No,None,Eligible,HBeAg-positive immune-active phase � treat.,,Eligible,,Eligible,"Eligibility and Rationale:
+- Eligible: HBV DNA > 20,000 IU/mL and ALT > 2xULN, regardless of fibrosis stage (Grade B) [SASLT 2021, Page 6]
+- Moderate necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]
+
+Treatment Recommendations:
+- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]
+
+Monitoring and Follow-up:
+- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]
+
+Special Considerations:
+- None applicable to this patient [SASLT 2021, Pages 6-10]
+
+References:
+- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
+,,,,,,,,,,,,,,,,,,,,,,

core/hbv_assessment.py

@@ -144,7 +144,9 @@ SASLT_GUIDELINES = """
 • The treatment of choice is the long-term administration of a potent nucleos(t)ide analogue NA with a high barrier to resistance, regardless of the severity of liver disease (Grade A) [SASLT 2021, p. 8]
 • Preferred regimens are ETV, TDF and TAF as monotherapies (Grade A) [SASLT 2021, p. 8]
 • LAM, ADV and TBV are not recommended in the treatment of CHB (Grade A) [SASLT 2021, p. 8]
-
+• TAF has demonstrated superior renal and bone density safety profiles compared with TDF in head-to-head trials [SASLT 2021, p. 8]
+• International guidelines recommend switching individuals at high risk for bone or renal disease from TDF to either TAF or ETV [SASLT 2021, p. 8]
+• TAF maintains a better safety profile unless the patient's creatinine clearance (CrCl) is less than 15 mL/minute [SASLT 2021, p. 8]
 
 ### 5. HBV-HCV COINFECTION [SASLT 2021, p. 8-9]
 

test_assessment_fixed.py

@@ -218,8 +218,11 @@ def main():
         print(f"Result: {result}")
         
         # Update dataframe
-        df.at[idx, 'Eligibility'] = result.get('eligible')
-        df.at[idx, 'Rationale'] = result.get('recommendations', '')
+        df.at[idx, 'Eligibility from ACTIVATE 2'] = (
+            'eligible' if result.get('eligible') is True else (
+            'not eligible' if result.get('eligible') is False else ''
+        ))
+        df.at[idx, 'Rational from ACTIVATE 2'] = result.get('recommendations', '')
     
     # Save results
     print(f"\nSaving results to {output_file}...")
@@ -235,4 +238,4 @@ def main():
 
 
 if __name__ == "__main__":
-    main()
+    main()